Last reviewed · How we verify
NCT06185205: ASHBY
ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy
Phase 2 trial testing Accelerated partial breast irradiation in Breast Cancer in 170 participants. Currently enrolling.
31 January 2031
Quick facts
| Lead sponsor | Virginia Commonwealth University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 170 |
| Start date | 12 December 2023 |
| Primary completion | 31 January 2031 |
| Estimated completion | 31 January 2033 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Accelerated partial breast irradiation — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Virginia Commonwealth University
Who can join
Adults 45 to 79, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to compare any good and bad effects of giving radiation treatment for breast cancer in 3 treatments over about 2 days.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06185205
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Accelerated partial breast irradiation
Trials testing the same drug.
- NCT02806258 — Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs · Phase 1, PHASE2 · terminated
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Virginia Commonwealth University trials
Trials by the same sponsor.
- NCT05936931 — Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening · NA · not yet recruiting
- NCT07365839 — Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma · Phase 1 · not yet recruiting
- NCT07178158 — Enhancing Addiction Treatment Through Psychoeducation · NA · not yet recruiting
- NCT07531316 — Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers · Phase 1 · not yet recruiting
- NCT07426913 — Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06185205 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Virginia Commonwealth University
- Last refreshed: 21 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06185205.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing